Differential retinoblastoma and p16(INK4A) protein expression in neuroendocrine tumors of the lung

Cancer

Volumn 88, Issue 3, 2000, Pages 550-556

  Dosaka Akita, Hirotoshi ^a   Cagle, Philip T ^b   Hiroumi, Hiromitsu ^a   Fujita, Masahiro ^c   Yamashita, Motoyuki ^d   Sharma, Anupama ^e   Kawakami, Yoshikazu ^a   Benedict, William F ^d  

^a HOKKAIDO UNIVERSITY   (Japan)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HOKKAIDO CANCER CENTER   (Japan)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Diagnostic marker; Immunohistochemistry; Neuroendocrine tumors of the lung; P16(INK4A) protein; Retinoblastoma protein

Indexed keywords

PROTEIN P16; RETINOBLASTOMA PROTEIN;

ARTICLE; CANCER DIAGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; LUNG TUMOR; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOID TUMOR; CARCINOMA, NEUROENDOCRINE; CARCINOMA, SMALL CELL; CELL NUCLEUS; COLORING AGENTS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; RETINOBLASTOMA PROTEIN; SINGLE-BLIND METHOD; SMOKING;

EID: 0034142330     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000201)88:3<550::AID-CNCR9>3.0.CO;2-D     Document Type: Article

References (43)

1. Warren WH, Faber LP, Gould VE. Neuroendocrine neoplasms of the lung. J Thorac Cardiovasc Surg 1989;98:321-32.
2. Colby TV, Koss MN, Travis WD. Carcinoid and other neuroendocrine tumors. In: Rosai J and Sobin LH, editors. Atlas of tumor pathology. 3rd series, Fascicle 13. Tumors of the lower respiratory tract. Washington, DC: Armed Forces Institute of Pathology, 1995;287-317.
3. Cagle PT. Tumors of the lung (excluding lymphoid tumors). In: Thurlbeck WM, Churg AM, editors. Pathology of the lung. 2nd edition. New York: Thieme Medical Publishers, Inc., 1995;437-552.
4. Linnoila RI. Spectrum of neuroendocrine differentiation in lung cancer cell line featured by cytomorphology, markers, and their corresponding tumors. J Cell Biochem (Suppl) 1996;24:9-106.
5. Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB Jr., Nieman L, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. Am J Surg Pathol 1991;15:529-53.
6. Colby TV, Koss MN, Travis WD. Small cell carcinoma and large cell neuroendocrine carcinoma. In: Rosai J and Sobin LH, editors. Atlas of tumor pathology. 3rd series, Fascicle 13. Tumors of the lower respiratory tract. Washington, DC: Armed Forces Institute of Pathology, 1995:235-57.
7. Travis WD, Gal AA, Colby TV, Klimstra DS, Falk R, Koss MN. Reproducibility of neuroendocrine lung tumor classification. Hum Pathol 1998;29:272-9.
8. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998;22:934-44.
9. Barbareschi M, Girlando S, Mauri FA, Arrigoni G, Laurino L, Palma PD, et al. Tumor suppressor gene products, proliferation, and differentiation markers in lung neuroendocrine neoplasms. J Pathol 1992;166:343-50.
10. Lohmann DR, Fesseler B, Putz B, Reich U, Bohm J, Prauer H, et al. Infrequent mutations of the p53 gene in pulmonary carcinoid tumors. Cancer Res 1993;53:5797-801.
11. Gouyer V, Gazzeri S, Brambilla E, Bolon I, Moro D, Perron P, et al. Loss of heterozygosity at the RB locus correlates with loss of RB protein in primary malignant neuroendocrine lung carcinomas. Int J Cancer 1994;58:818-24.
12. Lai S, Brauch H, Knutsen T, Johnson BE, Nau MM, Mitsudomi T, et al. Molecular genetic characterization of neuroendocrine lung cancer cell lines. Anticancer Res 1995;15: 225-32.
13. Jiang S, Kameya T, Sato Y, Yanase N, Yoshimura H, Kodama T. Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation. Am J Pathol 1996;148:837-46.
14. Przygodzki RM, Finkelstein SD, Langer JC, Swalsky PA, Fishback N, Bakker A, et al. Analysis of p53, K-ras, and c-raf-1 in pulmonary neuroendocrine tumors. Am J Pathol 1996;148: 1531-41.
15. Hurr K, Kemp B, Silver SA, El-Naggar AK. Microsatellite alteration at chromosome 3p loci in neuroendocrine and nonneuroendocrine lung tumors. Am J Pathol 1996;149:613-20.
16. Brambilla E, Negoescu A, Gazzeri S, Lantuejoul S, Moro D, Brambilla C, et al. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 1996;149: 1941-52.
17. Rusch VW, Klimstra DS, Venkatraman ES. Molecular markers help characterize neuroendocrine lung tumors. Ann Thorac Surg 1996;62:798-810.
18. Debelenko LV, Brambilla E, Agarwal SK, Swalwell JI, Kester MB, Lubensky IA, et al. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet 1997;6:2285-90.
19. Kovatich AK, Friedland DM, Druck T, Hadaczek P, Huebner K, Comis RL, et al. Molecular alterations to human chromosome 3p loci in neuroendocrine lung tumors. Cancer 1998; 83:1109-17.
20. INK4a gene is frequently lost in small cell lung cancer. Cancer Res 1998;58:3926-31.
21. Walch AK, Zitzelsberger HF, Aubele MM, Mattis AE, Bauchinger M, Candidus S, et al. Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization. Am J Pathol 1998;153:1089-98.
22. Onuki N, Wistuba I, Travis WD, Virmani AK, Yashima K, Brambilla E, et al. Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer 1999;85:600-7.
23. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30.
24. Benedict WF, Xu H, Hu S, Takahashi R. Role of the retinoblastoma gene in the initiation and progression of human cancer. J Clin Invest 1990;85:988-93.
25. Xu H, Hu S, Benedict WF. Lack of nuclear RB protein staining in G0/middle G1 cells: correlation to changes in total RB protein level. Oncogene 1991;6:1139-46.
26. Xu H, Hu S, Cagle PT, Moore GE, Benedict WF. Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res 1991;51:2735-9.
27. Zhang X, Xu H, Murakami Y, Sachse R, Yashima K, Hirohashi S, et al. Deletion of chromosome 1q, mutations in retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 1994;54:4177-82.
28. Cagle PT, El-Naggar AK, Xu H, Hu S, Benedict WF. Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Am J Pathol 1997;150:393-400.
29. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
30. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368:753-6.
31. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
32. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, et al. Retinoblastoma protein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature 1995;375:503-6.
33. INK4 protein is restricted to the subset of lung cancer cell line that retains wild type RB. Oncogene 1994;9: 3375-8.
34. INK4 expression in primary lung cancers and cell lines. Cancer Res 1995;55:505-9.
35. Kelley MJ, Nakagawa K, Steinberg SM, Mulshine JL, Kamb A, Johnson BE. Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. J Natl Cancer Inst 1995;87:756-61.
36. INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 1995;55:6006-11.
37. INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res 1996;56:5557-62.
38. Benedict WF, Lerner SP, Zhou J, Shen X, Tokunaga H, Czerniak B. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 1999;18:1197-203.
39. Logothetis CJ, Xu H, Ro JY, Hu S, Sahin A, Ordonez N, et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 1992;84:1256-61.
40. Xu H, Hu S, Hashimoto T, Takahashi R, Benedict WF. The retinoblastoma susceptibility gene product: a characteristic pattern in normal cells and abnormal expression in malignant cells. Oncogene 1989;4:807-21.
41. Xu H, Quinlan DC, Davidson AG, Hu S, Summers CL, Li J, et al. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst 1994;86:695-9.
42. Mehta CR, Patel NR. A network algorithm for performing Fisher's exact test in r × c contingency tables. J Am Stat Assoc 1983;78:427-34.
43. Arrigoni MG, Woolner LB, Bernatz PE. Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg 1972;64: 413-21.